Good afternoon! Novo Nordisk and Eli Lilly have so far dominated the booming market for a class of weight loss and diabetes drugs.
But Eli Lilly may be starting to gain an edge over its Danish competitor in the two-horse race to capitalize on the soaring demand for those treatments, also known as GLP-1s.
That became clear last week after the pair reported their respective second-quarter earnings.
“Lilly is pulling ahead in the metabolic duopoly,” BMO Capital Markets analyst Evan Seigerman said in a research note Thursday.
On Aug. 7, Novo Nordisk trimmed its full-year profit outlook after reporting that quarterly sales of its weight loss injection Wegovy came in well below Wall Street’s expectations. The disappointing result came due to higher-than-expected price concessions to pharmacy benefit managers, which negotiate drug discounts with manufacturers on behalf of insurers, executives said on a conference call last week.
Revenue from its blockbuster diabetes drug Ozempic also failed to meet estimates for the period. The company’s stock plunged.
Still, Novo Nordisk slightly increased its guidance for full-year sales growth.
Eli Lilly’s quarterly report one day later was an entirely different story. The Indianapolis-based company’s weight loss injection Zepbound and diabetes treatment Mounjaro smashed expectations for the second quarter.
Eli Lilly hiked its 2024 revenue outlook by $3 billion and raised its full-year profit guidance on the strong performance of Zepbound and Mounjaro and “improved clarity” into the company’s production expansions for those drugs.
Unlike Novo Nordisk, Eli Lilly benefited from higher U.S. prices of Mounjaro in the quarter as use of savings card programs for the drug decreased. Executives said they expect “stable pricing” for Mounjaro and Zepbound across the last two quarters of 2024.
Eli Lilly shares closed more than 9% higher on Thursday.
Several analysts were particularly pleased with Eli Lilly’s positive manufacturing updates. Demand for weight loss and diabetes drugs is outstripping supply in the U.S., so companies that can quickly get more of a product to patients can gain an edge in the space.
All doses of Mounjaro and Zepbound are now listed as available on the Food and Drug Administration’s drug shortage database. Meanwhile, some doses of Wegovy are in limited supply as Novo Nordisk pours billions into its own manufacturing expansion efforts.
In a research note Thursday, Bank of America analysts raised their combined revenue forecast for Mounjaro and Zepbound to $19.7 billion in 2024, $31 billion in 2025 and $38.5 billion in 2026 because they have “gotten more comfortable with supply dynamics.”
The analysts said there could still be intermittent supply shortages of Mounjaro and Zepbound in the near term “as access improves and physicians get more comfortable with the availability of supply.” But they applauded Eli Lilly’s progress towards beefing up its manufacturing footprint and supply.
For example, Eli Lilly CEO David Ricks said on an earnings call Thursday the company has built six manufacturing plants, some of which are already ramping up, and hired thousands of workers to increase production. The company acquired another site earlier this year.
Eli Lilly expects incretin drug production – another term for weight loss and diabetes treatments – in the second half of 2024 to be 50% higher than it was during the same period last year, he added.
Ricks said Eli Lilly’s ability to scale up manufacturing of Zepbound and Mounjaro makes the company confident it can compete with newcomers to the weight loss and diabetes drug market that may not have the same capacity.
“I don’t know if it’s a barrier, but it certainly is work to do: Scaling manufacturing,” Ricks said.
“You’re talking about making things on the billion scale, which takes time and is technically difficult and very capital-intensive,” he continued. “So, of course, competitors will have to come. But there’s a large road ahead for all these [other drugmakers] that the two leading companies have already walked in large part.”
